Breast Cancer
Conditions
Keywords
breast cancer, vacuum assisted breast biopsy
Brief summary
Pilot study on patients with invasive ductal breast cancer triple negative or receptor tyrosine-protein kinase erbB-2 (HER2) overexpressed, any axillary lymphnodes status (any cN), candidates to neoadjuvant chemotherapy. The principal endpoint of the study will be the accuracy of the result of the histological examination of the Vacuum- Assisted Breast Biopsy (VABB) performed pre-surgery in comparison to the result of the histological examination of the definitive surgical intervention in patients with radiological complete response at Magnetic resonance imaging (MRI) done after the end of neoadjuvant chemotherapy.
Detailed description
The study articulates in five phases: Phase one: acquisition of the informed consent followed by positioning a clip into the cancer bed (by radiologist) if not already present; Phase two: after radiological confirmation of pathological Complete Response (pCR) done performing breast ultrasound, MRI and 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography (18-FDG-PET) after neoadjuvant chemotherapy the patient becomes candidate to VABB pre surgery. Phase three: the patient has VABB within 15 day from the term of neoadjuvant chemotherapy Phase four: definitive surgical intervention within 30 days from the end of the neoadjuvant chemotherapy Phase five: verification of correspondence between histology of VABB and definitive histology. The study hypothesis is that VABB could be used in the patients with pCR to the imaging post-neoadjuvant chemotherapy to confirm sensibility and specificity of 18 FDG TC PET and breast MRI to show the absence of breast cancer. The use of VABB with negative histology result could bring to a therapeutic gold standard without over surgical treatment
Interventions
PROCEDUREvacuum-assisted breast biopsy
patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
Sponsors
European Institute of Oncology
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* age ≥ 18 aa; * histological diagnosis done at European Institute of Oncology (if not, to does revision of pathological material); * invasive ductal breast cancer triple negative or HER2 overexpressed, any cN; * neoadjuvant standard systemic treatment after surgery +/- trastuzumab; * propose of conservative or demolitive surgery; * M0 * cancer bed identified pre neoadjuvant chemotherapy by clip
Exclusion criteria
* multicentric or bilateral breast cancer * mammography microcalcifications * in situ breast carcinoma * positive anamnesis for previous breast cancer * positive anamnesis for medical or psychological conditions that prevent membership study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the accuracy of histological examination of the VABB performed pre-surgery | 45 days | Identification of percentage of cases with correspondence between histology of VABB presurgery and histology of definitive surgery in patients with complete radiological response after neoadjuvant chemotherapy |
Countries
Italy
Outcome results
None listed